Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
|Webcasts|November 29, 2022
Key Considerations When Selecting an mRNA CDMO Partner
Author(s)Samsung Biologics
Webinar Date/Time: Thursday, December 8, 2022 at 11am EST | 10am CST | 8 am PST
This webinar will highlight the challenges in in the field of mRNA-based therapeutics, a strategy to design mRNA-LNP process for at-scale manufacturing, and the importance of end-to-end service.
Register Free:
Event Overview:
CDMO competition can be expected to intensify since mRNA manufacturing capacity and CDMOs’ capabilities both expanded significantly to meet the need associated with the pandemic. From a technical standpoint, the processes associated with mRNA manufacture generally are still new; this is pioneering work. This webinar will highlight the challenges in in the field of mRNA-based therapeutics, a strategy to design mRNA-LNP process for at-scale manufacturing, and the importance of end-to-end service. Lastly, the in-house capability of Samsung Biologics as mRNA CDMO company will be introduced.
Key Learning Objectives:
- Criteria to consider when choosing a mRNA CDMO partner
- How to develop mRNA-LNP process
- Importance of the end-to-end CDMO service
- Samsung Biologics mRNA services’ Strength
Speakers:
Pierre Catignol
Executive Vice President, Head of Manufacturing
Samsung Biologics
Pierre Catignol is the Executive Vice President and Head of Manufacturing at Samsung Biologics. He is a recognized industry expert with a demonstrated history of 26+ years in the biopharmaceutical and pharmaceutical industry. Prior to joining Samsung Biologics, Pierre held a leadership role at Lonza serving as the Head of the Portsmouth, NH (USA) and Porriño, Spain sites. He also served as Site Head at Virbac & Sanofi Pasteur, as well as Senior Vice President of Technical Operations & Supply Chain at Stallergenes Greer earlier in his career. Pierre holds a master's degree in general engineering from ECAM LaSalle.
Eunseo (Ency) Lee
Senior Scientist
Samsung Biologics
Eunseo (Ency) Lee, Ph.D is the Senior Scientist of mRNA T/F at Samsung Biologics. After joining Samsung Biologics in 2021, she has led the tech transfer project in both lab- and at-scale lipid nanoparticle manufacturing process. She holds a Master/Ph.D degree in Chemical and Biological Engineering from Seoul National University, South Korea, and a bachelor’s degree in Chemical Engineering from University of Notre Dame, USA.
Register Free:
Related to this article
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
Trending on Pharmaceutical Technology
1
What the Olanzapine Depot Approval Means for CMC Teams
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
Q&A: Patient-Centric Drug Development Should Start at Product Definition
4
PharmTech AI Pulse Check: AI Watermark Vulnerability
5